The biotech firm reported a net loss of $40.6 million for the second quarter of 2026, a slight improvement from the $41.6 million loss recorded during the same period in 2025. Revenue for the quarter reached $10.1 million, reflecting a marginal dip from the previous year’s $11.2 million. Despite the ongoing losses typical of a clinical-stage developer, management emphasized that their balance sheet is fortified by a successful stock offering in April 2026, which generated $373.8 million in gross proceeds.
In section Releases
Nektar Therapeutics Secures Financial Runway for Phase 3 Trials
With over $1 billion in cash and marketable securities, Nektar Therapeutics has solidified its financial position to sustain operations through the third quarter of 2028. The company is now aggressively advancing its lead immunology program, rezpegaldesleukin, into critical Phase 3 clinical trials for atopic dermatitis and alopecia areata.
Research and development spending climbed to $39.1 million this quarter, up from $29.9 million a year ago, as the company ramped up manufacturing and initiated the ZENITH AD program. Conversely, general and administrative expenses saw a sharp decline, dropping to $12.8 million from $17.1 million, largely due to reduced legal costs. CEO Howard W. Robin confirmed that the company remains on track for its first BLA submission for rezpegaldesleukin in 2029, with initial Phase 3 data readouts anticipated by mid-2028.
Comments (0)
No comments yet. Be the first!